Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

100% User Fees For US FDA? Trump Budget Revives Important Issue For Industry – But Not This Year

Executive Summary

Trump Administration’s surprising call for increased user fees probably won’t have much impact on pending reauthorization process, but it does put on the table an important question for the biopharma industry to consider for the long term: should FDA be fully funded by user fees?

You may also be interested in...



The Latest Furor Over Trump’s Drug Pricing Plan

Did the head of the Office and Management & Budget really endorse Part D rebates? Like so much about the Trump Administration’s response to drug pricing, there is probably a lot less to the story than it sounds.

Perspectives On Health Reform, User Fees With Cowen's Chris Krueger

Cowen's Washington Strategist Chris Krueger discusses US health reform, drug pricing legislation and user fees in new podcast.

Inspection Delays Remain For Novel Approvals By US FDA; Will Quality Office Help?

Final assessment of the PDUFA V new drug review 'Program' flagged inspection delays as a continued sticking point for on-time approvals. US FDA says consolidation of manufacturing oversight under the agency’s new quality office will help.

Related Content

Topics

UsernamePublicRestriction

Register

PS120300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel